Endothelial function in renal transplant recipients is associated with circulating nitric oxide, ACE inhibitor use and time after transplantation

Vascular Disease Prevention

Volumn 3, Issue 3, 2006, Pages 229-234

  Åsberg, Anders ^a   Hjelmesæth, Jøran ^a   Voytovich, Monica H ^a   Hartmann, Anders ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; NITRIC OXIDE; STEROID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; PRIORITY JOURNAL;

EID: 33746927211     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727006778019031     Document Type: Article

References (47)

1. Tyroler HA. Coronary heart disease epidemiology in the 21st century. Epidemiol Rev 2000; 22: 7-13.
2. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
3. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
4. Gokce N, Keaney JF Jr., Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-1775.
5. Terasaki P, Mickey MR, Iwaki Y, et al. Long-term survival of kidney grafts. Transplant Proc 1989; 21: 615-617.
6. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
7. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100-1106.
8. Hausberg M, Kisters K, Kosch M, Rahn KH, Barenbrock M. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55: 1104-1110.
9. Andreassen AK, Kirkeboen KA, Gullestad L, Simonsen S, Kvernebo K. Effect of heart transplantation on impaired peripheral microvascular perfusion and reactivity in congestive heart failure. Int J Cardiol 1998; 65: 33-40.
10. Graff J, Klinkhardt U, Harder S, et al. Immunosuppressive therapy regimen and platelet activation in renal transplant patients. Clin Pharmacol Ther 2002; 72: 411-418.
11. Andreassen AK, Gullestad L, Holm T, Simonsen S, Kvernebo K. Endothelium-dependent vasodilation of the skin microcirculation in heart transplant recipients. Clin Transplant 1998; 12: 324-332.
12. Wierzbicki AS. The role of lipid lowering in transplantation. Int J Clin Pract 1999; 53: 54-59.
13. Holm T, Aukrust P, Andreassen AK, et al. Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines. Clin Transplant 2000; 14: 218-225.
14. Textor SC, Wilson DJ, Lerman A, et al. Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation. Transplantation 1992; 54: 74-80.
15. Åsberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1465-1470.
16. Åsberg A, Berg KJ, Hartmann A. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res 2000; 60: 81-90.
17. Åsberg A, Holm T, Vassbotn T, Andreassen AK, Hartmann A. Nonspecific microvascular vasodilation during iontophoresis is attenuated by application of hyperosmolar saline. Microvasc Res 1999; 58: 41-48.
18. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337-1344.
19. Voytovich MH, Simonsen C, Jenssen T, Hjelmesæth J, Åsberg A, Hartmann A. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 413-418.
20. Voytovich MH, Åsberg A, Hjelmesæth J, Jenssen T, Hartmann A. Association between insulin resitance and endothelial dysfunction in renal transplant recipients. Clin Transplant 2006; 20: 195-199.
21. Åsberg A, Hartmann A, Fjeldså E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 2001; 16: 1920-1924.
22. Åsberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplant 2003; 17: 385-390.
23. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
24. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41: 892-896.
25. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-119.
26. Kocak H, Ceken K, Yavuz A, et al. Effect of renal transplantation on endothelial function in haemodialysis patients. Nephrol Dial Transplant 2005; 6.
27. Oflaz H, Pusuroglu H, Genchallac H, et al. Endothelial function is more impaired in hemodialysis patients than renal transplant recipients. Clin Transplant 2003; 17: 528-533.
28. Passauer J, Bussemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation 2003; 75: 1907-1910.
29. Millgård J, Hägg A, Sarabi M, Lind L. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 1998; 12: 511-516.
30. Millgård J, Lind L. Divergent effects of different antihypertensive drugs on endothelium- dependent vasodilation in the human forearm. J Cardiovasc Pharmacol 1998; 32: 406-412.
31. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
32. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-282.
33. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
35. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
36. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
37. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
38. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287: 3215-3222.
39. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
40. Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
41. Holm T, Andreassen AK, Ueland T, et al. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 2001; 87: 815-818, A819.
42. Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001; 59: 1473-1479.
43. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36: 410-416.
44. Perticone F, Ceravolo R, Maio R, et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000; 152: 511-518.
45. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mugge A, Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2005; 104: 176-180.
46. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-691.
47. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens 2001; 19: 415-420.